<p>藥明康德公司（NYSE:PRGO - 獲取免費報告）目前被五家評級機構給予了 “持有” 的平均推薦，Marketbeat 報道稱。三位研究分析師對該股票給予了持有推薦，另外兩位則給予了買入推薦。在過去一年中，發佈報告的經紀人對該股票的平均一年目標價格為 35.00 美元。</p>
<p>幾位股票分析師對該公司進行了評論。傑富瑞金融集團在 9 月 23 日的報告中重申了 “持有” 評級，並將藥明康德的目標價格下調至 30.00 美元（之前為 50.00 美元）。派珀·桑德勒在 1 月 6 日的研究報告中將藥明康德的股票評級從 “增持” 下調至 “中性”，並將其目標價格從 34.00 美元下調至 27.00 美元。Canaccord Genuity Group 在 9 月 30 日的研究報告中重申了 “買入” 評級，並將藥明康德的目標價格設定為 42.00 美元。StockNews.com 在週六的研究報告中將藥明康德的股票評級從 “買入” 下調至 “持有”。最後，Argus 在週二的研究報告中將藥明康德的股票評級從 “買入” 下調至 “持有”。</p>
<p><strong>獲取我們關於 PRGO 的最新研究報告</strong></p>
<h2>藥明康德股票表現</h2>
<p>週二中午交易時，PRGO 的股票下跌了 0.58 美元，報 23.76 美元。該公司的股票交易量為 98,548 股，而其平均交易量為 1,370,925 股。藥明康德的股價一年低點為 23.73 美元，一年高點為 33.96 美元。該股票的 50 日移動平均線為 26.71 美元，200 日移動平均線為 26.80 美元。該公司的市值為 32.4 億美元，市盈率為-20.31，貝塔係數為 0.53。該公司的債務與股本比率為 0.94，速動比率為 1.77，流動比率為 2.56。</p>
<p>藥明康德（NYSE:PRGO - 獲取免費報告）最近於 11 月 6 日發佈了季度財報。該公司報告每股收益（EPS）為 0.81 美元，符合市場共識預期的 0.81 美元。該公司的季度收入為 10.9 億美元，而分析師預期為 11.2 億美元。藥明康德的淨利潤率為-3.64%，股本回報率為 7.38%。該公司的季度收入同比下降了 3.2%。去年同期，該公司每股收益為 0.64 美元。整體來看，賣方分析師預計藥明康德在當前年度將發佈 2.56 美元的每股收益。</p>
<h2>藥明康德宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，該分紅於 12 月 17 日支付。11 月 29 日的股東記錄顯示，股東獲得了 0.276 美元的分紅。這代表着每年 1.10 美元的分紅和 4.65% 的分紅收益率。除息日期為 11 月 29 日。藥明康德的派息比率為-94.02%。</p>
<h2>藥明康德的內部活動</h2>
<p>在其他消息中，董事傑弗裏·B·金德勒於 12 月 9 日以 28.27 美元的平均價格出售了 17,598 股股票，總交易額為 497,495.46 美元。出售後，該董事現在持有 5,409 股公司股票，價值約 152,912.43 美元。這代表着其持股比例下降了 76.49%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。當前，0.70% 的股票由內部人士持有。</p>
<h2>機構投資者對藥明康德的看法</h2>
<p>對沖基金和其他機構投資者最近對該公司的持倉進行了調整。德克薩斯州永久學校基金公司在第二季度增持了藥明康德的股份，增幅為 1.2%。德克薩斯州永久學校基金公司現在持有 119,298 股公司股票，價值 3,064,000 美元，此前在該期間內增持了 1,357 股。美國世紀公司在第二季度增持了藥明康德的股份，增幅為 13.7%。美國世紀公司現在持有 24,334 股公司股票，價值 625,000 美元，此前在上個季度增持了 2,929 股。Dimensional Fund Advisors LP 在第二季度增持了藥明康德的股份，增幅為 3.6%。Dimensional Fund Advisors LP 現在持有 7,162,656 股公司股票，價值 183,935,000 美元，此前在該期間內增持了 249,640 股。明治安田資產管理有限公司在第二季度增持了藥明康德的股份，增幅為 4.2%。明治安田資產管理有限公司現在持有 301,570 股公司股票，價值 7,744,000 美元，此前在上個季度增持了 12,254 股。最後，合併銀行在第二季度增持了藥明康德的股份，增幅為 3.3%。合併銀行現在持有 85,350 股公司股票，價值 2,192,000 美元，此前在上個季度增持了 2,752 股。95.91% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於藥明康德</h2>
<p>（獲取免費報告）</p>
<p>藥明康德公司在美國、歐洲及國際市場提供非處方健康和保健解決方案，以提升個人健康。它通過消費者自我護理美洲和消費者自我護理國際兩個部門運營。該公司開發、製造、營銷和分銷自我護理消費品，包括上呼吸道產品（如止咳藥、祛痰藥和鼻竇及過敏緩解藥）；營養產品，包括嬰兒配方奶粉和營養飲料；消化健康產品，包括抗酸藥、止瀉藥和抗胃灼熱藥；止痛和助眠產品，包括止痛藥和退燒藥；以及口腔護理產品，包括牙刷、牙刷替換頭、牙線、牙線棒、美白產品和牙刷保護套。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票超過培瑞克</li>
<li>製造業股票投資</li>
<li>美聯儲在 2025 年加息的可能性大於降息</li>
<li>即將到來的 IPO 股票鎖定期解析</li>
<li>投資者通過尋求黃金和石油避險來應對不確定性</li>
<li>3 只可以提升您投資組合的家居改善股票</li>
<li>Archer Aviation 股價下滑，現在 2025 年價格便宜</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSR08?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSR08"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>您現在應該投資 1,000 美元在培瑞克嗎？</h2>
<p>在您考慮培瑞克之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而培瑞克並不在名單上。</p>
<p>雖然培瑞克目前在分析師中被評為 “持有”，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

培瑞克

<p>Perrigo Company plc（紐約證券交易所代碼：PRGO）獲得了五位分析師的平均評級為 “持有”，其中三位推薦持有，二位推薦買入。平均目標價為 35.00 美元。最近的評級包括 Jefferies Financial Group 的持有評級，目標價為 30.00 美元，Piper Sandler 的下調至中性，目標價為 27.00 美元，以及 Canaccord Genuity 的買入評級，目標價為 42.00 美元。該股票目前交易價格為 23.76 美元，市值為 32.4 億美元。Perrigo 還宣佈了每季度 0.276 美元的股息，收益率為 4.65%</p>

<p>Perrigo Company plc (NYSE:PRGO - Get Free Report) has been given an average recommendation of &#34;Hold&#34; by the five ratings firms that are currently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $35.00.</p>
<div class="lb-trans"><p>藥明康德公司（NYSE:PRGO - 獲取免費報告）目前被五家評級機構給予了 “持有” 的平均推薦，Marketbeat 報道稱。三位研究分析師對該股票給予了持有推薦，另外兩位則給予了買入推薦。在過去一年中，發佈報告的經紀人對該股票的平均一年目標價格為 35.00 美元。</p>
</div><p>Several equities analysts have commented on the company. Jefferies Financial Group reaffirmed a &#34;hold&#34; rating and issued a $30.00 price target (down previously from $50.00) on shares of Perrigo in a report on Monday, September 23rd. Piper Sandler downgraded shares of Perrigo from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and decreased their price target for the stock from $34.00 to $27.00 in a research note on Monday, January 6th. Canaccord Genuity Group restated a &#34;buy&#34; rating and issued a $42.00 price objective on shares of Perrigo in a research note on Monday, September 30th. StockNews.com lowered shares of Perrigo from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday. Finally, Argus lowered shares of Perrigo from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday.</p>
<div class="lb-trans"><p>幾位股票分析師對該公司進行了評論。傑富瑞金融集團在 9 月 23 日的報告中重申了 “持有” 評級，並將藥明康德的目標價格下調至 30.00 美元（之前為 50.00 美元）。派珀·桑德勒在 1 月 6 日的研究報告中將藥明康德的股票評級從 “增持” 下調至 “中性”，並將其目標價格從 34.00 美元下調至 27.00 美元。Canaccord Genuity Group 在 9 月 30 日的研究報告中重申了 “買入” 評級，並將藥明康德的目標價格設定為 42.00 美元。StockNews.com 在週六的研究報告中將藥明康德的股票評級從 “買入” 下調至 “持有”。最後，Argus 在週二的研究報告中將藥明康德的股票評級從 “買入” 下調至 “持有”。</p>
</div><p><strong>Get Our Latest Research Report on PRGO</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 PRGO 的最新研究報告</strong></p>
</div><h2>Perrigo Stock Performance</h2>
<div class="lb-trans"><h2>藥明康德股票表現</h2>
</div><p>Shares of PRGO traded down $0.58 during mid-day trading on Tuesday, hitting $23.76. The company's stock had a trading volume of 98,548 shares, compared to its average volume of 1,370,925. Perrigo has a one year low of $23.73 and a one year high of $33.96. The stock's 50-day moving average is $26.71 and its two-hundred day moving average is $26.80. The firm has a market capitalization of $3.24 billion, a PE ratio of -20.31 and a beta of 0.53. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56.</p>
<div class="lb-trans"><p>週二中午交易時，PRGO 的股票下跌了 0.58 美元，報 23.76 美元。該公司的股票交易量為 98,548 股，而其平均交易量為 1,370,925 股。藥明康德的股價一年低點為 23.73 美元，一年高點為 33.96 美元。該股票的 50 日移動平均線為 26.71 美元，200 日移動平均線為 26.80 美元。該公司的市值為 32.4 億美元，市盈率為-20.31，貝塔係數為 0.53。該公司的債務與股本比率為 0.94，速動比率為 1.77，流動比率為 2.56。</p>
</div><p>Perrigo (NYSE:PRGO - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.81 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.81. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.12 billion. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The business's quarterly revenue was down 3.2% on a year-over-year basis. During the same period last year, the business posted $0.64 EPS. As a group, sell-side analysts anticipate that Perrigo will post 2.56 EPS for the current year.</p>
<div class="lb-trans"><p>藥明康德（NYSE:PRGO - 獲取免費報告）最近於 11 月 6 日發佈了季度財報。該公司報告每股收益（EPS）為 0.81 美元，符合市場共識預期的 0.81 美元。該公司的季度收入為 10.9 億美元，而分析師預期為 11.2 億美元。藥明康德的淨利潤率為-3.64%，股本回報率為 7.38%。該公司的季度收入同比下降了 3.2%。去年同期，該公司每股收益為 0.64 美元。整體來看，賣方分析師預計藥明康德在當前年度將發佈 2.56 美元的每股收益。</p>
</div><h2>Perrigo Announces Dividend</h2>
<div class="lb-trans"><h2>藥明康德宣佈分紅</h2>
</div><p>The company also recently announced a quarterly dividend, which was paid on Tuesday, December 17th. Stockholders of record on Friday, November 29th were issued a $0.276 dividend. This represents a $1.10 annualized dividend and a dividend yield of 4.65%. The ex-dividend date was Friday, November 29th. Perrigo's payout ratio is -94.02%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，該分紅於 12 月 17 日支付。11 月 29 日的股東記錄顯示，股東獲得了 0.276 美元的分紅。這代表着每年 1.10 美元的分紅和 4.65% 的分紅收益率。除息日期為 11 月 29 日。藥明康德的派息比率為-94.02%。</p>
</div><h2>Insider Activity at Perrigo</h2>
<div class="lb-trans"><h2>藥明康德的內部活動</h2>
</div><p>In other news, Director Jeffrey B. Kindler sold 17,598 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $28.27, for a total transaction of $497,495.46. Following the sale, the director now owns 5,409 shares in the company, valued at approximately $152,912.43. This represents a 76.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. 0.70% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事傑弗裏·B·金德勒於 12 月 9 日以 28.27 美元的平均價格出售了 17,598 股股票，總交易額為 497,495.46 美元。出售後，該董事現在持有 5,409 股公司股票，價值約 152,912.43 美元。這代表着其持股比例下降了 76.49%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。當前，0.70% 的股票由內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Perrigo</h2>
<div class="lb-trans"><h2>機構投資者對藥明康德的看法</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the company. Texas Permanent School Fund Corp grew its position in shares of Perrigo by 1.2% during the 2nd quarter. Texas Permanent School Fund Corp now owns 119,298 shares of the company's stock worth $3,064,000 after buying an additional 1,357 shares during the period. American Century Companies Inc. raised its position in shares of Perrigo by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 24,334 shares of the company's stock valued at $625,000 after acquiring an additional 2,929 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Perrigo by 3.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 7,162,656 shares of the company's stock valued at $183,935,000 after purchasing an additional 249,640 shares during the period. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Perrigo by 4.2% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 301,570 shares of the company's stock worth $7,744,000 after purchasing an additional 12,254 shares during the last quarter. Finally, Amalgamated Bank boosted its position in shares of Perrigo by 3.3% in the 2nd quarter. Amalgamated Bank now owns 85,350 shares of the company's stock worth $2,192,000 after purchasing an additional 2,752 shares during the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近對該公司的持倉進行了調整。德克薩斯州永久學校基金公司在第二季度增持了藥明康德的股份，增幅為 1.2%。德克薩斯州永久學校基金公司現在持有 119,298 股公司股票，價值 3,064,000 美元，此前在該期間內增持了 1,357 股。美國世紀公司在第二季度增持了藥明康德的股份，增幅為 13.7%。美國世紀公司現在持有 24,334 股公司股票，價值 625,000 美元，此前在上個季度增持了 2,929 股。Dimensional Fund Advisors LP 在第二季度增持了藥明康德的股份，增幅為 3.6%。Dimensional Fund Advisors LP 現在持有 7,162,656 股公司股票，價值 183,935,000 美元，此前在該期間內增持了 249,640 股。明治安田資產管理有限公司在第二季度增持了藥明康德的股份，增幅為 4.2%。明治安田資產管理有限公司現在持有 301,570 股公司股票，價值 7,744,000 美元，此前在上個季度增持了 12,254 股。最後，合併銀行在第二季度增持了藥明康德的股份，增幅為 3.3%。合併銀行現在持有 85,350 股公司股票，價值 2,192,000 美元，此前在上個季度增持了 2,752 股。95.91% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Perrigo</h2>
<div class="lb-trans"><h2>關於藥明康德</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.</p>
<div class="lb-trans"><p>藥明康德公司在美國、歐洲及國際市場提供非處方健康和保健解決方案，以提升個人健康。它通過消費者自我護理美洲和消費者自我護理國際兩個部門運營。該公司開發、製造、營銷和分銷自我護理消費品，包括上呼吸道產品（如止咳藥、祛痰藥和鼻竇及過敏緩解藥）；營養產品，包括嬰兒配方奶粉和營養飲料；消化健康產品，包括抗酸藥、止瀉藥和抗胃灼熱藥；止痛和助眠產品，包括止痛藥和退燒藥；以及口腔護理產品，包括牙刷、牙刷替換頭、牙線、牙線棒、美白產品和牙刷保護套。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Perrigo</li>
<li>Manufacturing Stocks Investing</li>
<li>The Fed Is More Likely to Hike Than Cut Rates in 2025</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Archer Aviation Shares Slide, Now Bargain Priced for 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過培瑞克</li>
<li>製造業股票投資</li>
<li>美聯儲在 2025 年加息的可能性大於降息</li>
<li>即將到來的 IPO 股票鎖定期解析</li>
<li>投資者通過尋求黃金和石油避險來應對不確定性</li>
<li>3 只可以提升您投資組合的家居改善股票</li>
<li>Archer Aviation 股價下滑，現在 2025 年價格便宜</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSR08" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=PRGO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Perrigo Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在培瑞克嗎？</h2>
</div><p>Before you consider Perrigo, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮培瑞克之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perrigo wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而培瑞克並不在名單上。</p>
</div><p>While Perrigo currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然培瑞克目前在分析師中被評為 “持有”，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

培瑞克公司（紐約證券交易所代碼：PRGO）獲得分析師的平均評級為 “持有”